SCHEMBL13376457

SCHEMBL13376457

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3cc(-n4cnc(C)c4)cc(C(F)(F)F)c3)ccc1C)c(=O)n2-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR2E1 Q9Y466 3/20 0.55
▸ EPHB4 P54760 1/20 0.53
▸ CSF1R P07333 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ MAPT P10636 1/20 0.52
▸ LDLR P01130 2/20 0.51
▸ KIT P10721 2/20 0.51
▸ PCSK9 Q8NBP7 2/20 0.51
▸ ABL1 P00519 4/20 0.50
▸ BRAF P15056 4/20 0.49
▸ SRC P12931 2/20 0.49
▸ BCR P11274 2/20 0.49
▸ TNK2 Q07912 1/20 0.49
▸ MAP4K2 Q12851 1/20 0.49
▸ EGFR P00533 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ FYN P06241 1/20 0.49
▸ YES1 P07947 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13376410 0.90 CSF1R (0.56) NR2E1EPHB4CSF1RKDM4EPOLB
SCHEMBL502120 0.86 LYN (0.52) CSF1RABL1BRAFSRCTNK2
SCHEMBL10043776 0.86 SYK (0.65) ABL1BRAFLCKSYKRAF1
SCHEMBL10071745 0.85 CSF1R (0.52) CSF1RABL1BRAFSRCTNK2
SCHEMBL10072194 0.85 BRAF (0.51) CSF1RBRAFSRCTNK2MAP4K2
SCHEMBL13437981 0.84 SYK (0.46) CSF1RABL1BRAFSRCTNK2
SCHEMBL10071825 0.83 SYK (0.45) CSF1RABL1BRAFSRCTNK2
SCHEMBL10071826 0.80 LCK (0.53) CSF1RKITABL1BRAFSRC
SCHEMBL10043659 0.79 SYK (0.63) ABL1BRAFSRCLCKLYN
SCHEMBL10072021 0.79 SYK (0.59) ABL1BRAFLCKSYKRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC NR2E1 2149/4885EPHB4 326/4885CSF1R 89/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC NR2E1 2149/4885EPHB4 326/4885CSF1R 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback